Cardiff Oncology completes enrollment in Phase 2 onvansertib trial for RAS-mutated mCRC; Q1 cash $79.9M

Cardiff Oncology, Inc.

2025-Q1 EPS reported -$0.20 revenue$109,000

Completed enrollment in Phase 2 CRDF-004 trial of onvansertib + SoC for first-line RAS-mutated mCRC across 41 U.S. sites.
Received second USPTO patent (No. 12,263,173) for onvansertib + bev in all bev-naïve mCRC patients, expiring no earlier than 2043.
Cash and investments $79.9M as of March 31, 2025; projected runway into Q1 2027.
Q1 2025 operating expenses $14.5M (up from $11.1M YoY); net cash used in ops $12.8M (up from $7.7M YoY).
Additional CRDF-004 clinical data expected in first half of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.